- Home
- PAVM vs ADVB Comparison
PAVM vs ADVB Comparison
Compare PAVM & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- ADVB
- Stock Information
- Founded
- PAVM 2014
- ADVB 2014
- Country
- PAVM United States
- ADVB United States
- Employees
- PAVM N/A
- ADVB N/A
- Industry
- PAVM Medical/Dental Instruments
- ADVB Medical Specialities
- Sector
- PAVM Health Care
- ADVB Health Care
- Exchange
- PAVM Nasdaq
- ADVB Nasdaq
- Market Cap
- PAVM 8.0M
- ADVB 9.1M
- IPO Year
- PAVM 2016
- ADVB 2025
- Fundamental
- Price
- PAVM $0.45
- ADVB $0.42
- Analyst Decision
- PAVM Strong Buy
- ADVB
- Analyst Count
- PAVM 1
- ADVB 0
- Target Price
- PAVM $19.00
- ADVB N/A
- AVG Volume (30 Days)
- PAVM 376.9K
- ADVB 371.2K
- Earning Date
- PAVM 08-14-2025
- ADVB 11-03-2025
- Dividend Yield
- PAVM N/A
- ADVB N/A
- EPS Growth
- PAVM N/A
- ADVB N/A
- EPS
- PAVM 0.83
- ADVB N/A
- Revenue
- PAVM $1,020,000.00
- ADVB N/A
- Revenue This Year
- PAVM N/A
- ADVB N/A
- Revenue Next Year
- PAVM $455.63
- ADVB N/A
- P/E Ratio
- PAVM $0.54
- ADVB N/A
- Revenue Growth
- PAVM N/A
- ADVB N/A
- 52 Week Low
- PAVM $0.30
- ADVB $0.34
- 52 Week High
- PAVM $1.90
- ADVB $4.10
- Technical
- Relative Strength Index (RSI)
- PAVM 43.12
- ADVB N/A
- Support Level
- PAVM $0.42
- ADVB N/A
- Resistance Level
- PAVM $0.49
- ADVB N/A
- Average True Range (ATR)
- PAVM 0.04
- ADVB 0.00
- MACD
- PAVM 0.00
- ADVB 0.00
- Stochastic Oscillator
- PAVM 30.87
- ADVB 0.00
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About ADVB Advanced Biomed Inc. Common Stock
Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.